Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Expands Austin Operations With New Sequencing Facility
12:01pm, Tuesday, 26'th May 2026
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
06:00am, Tuesday, 26'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive p
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
05:05pm, Thursday, 21'st May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
01:31pm, Thursday, 21'st May 2026
NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
07:00am, Thursday, 21'st May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milesto
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
03:35pm, Wednesday, 20'th May 2026
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
07:00am, Wednesday, 20'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
11:50am, Monday, 18'th May 2026
Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
12:45pm, Friday, 15'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Sign
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
02:30pm, Sunday, 10'th May 2026
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (
Natera Q1 Earnings Call Highlights
04:08pm, Friday, 08'th May 2026
Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief E
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Natera (NTRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
08:11pm, Thursday, 07'th May 2026
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:00pm, Thursday, 07'th May 2026
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to
Natera Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Rece
